These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 18489843)

  • 1. Treating high-density lipoprotein cholesterol: a return to inhibition of cholesteryl ester transfer protein?
    Duriez P
    Curr Atheroscler Rep; 2008 Jun; 10(3):177-9. PubMed ID: 18489843
    [No Abstract]   [Full Text] [Related]  

  • 2. CETP inhibition.
    Duriez P
    Lancet; 2007 Dec; 370(9603):1882-3. PubMed ID: 18068495
    [No Abstract]   [Full Text] [Related]  

  • 3. Future of cholesteryl ester transfer protein inhibitors.
    Rader DJ; deGoma EM
    Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of cholesteryl ester transfer protein inhibitor on vitamin E transport should be studied.
    Masterjohn C
    Am Heart J; 2009 Jul; 158(1):e11; author reply e13. PubMed ID: 19540377
    [No Abstract]   [Full Text] [Related]  

  • 5. Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme.
    Landmesser U; von Eckardstein A; Kastelein J; Deanfield J; Lüscher TF
    Eur Heart J; 2012 Jul; 33(14):1712-5. PubMed ID: 22696435
    [No Abstract]   [Full Text] [Related]  

  • 6. Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis.
    Li C; Zhang W; Zhou F; Chen C; Zhou L; Li Y; Liu L; Pei F; Luo H; Hu Z; Cai J; Zeng C
    PLoS One; 2013; 8(10):e77049. PubMed ID: 24204732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When good cholesterol turns bad: the evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein.
    Oram JF; Heinecke JW
    Curr Atheroscler Rep; 2007 Dec; 9(6):425-7. PubMed ID: 18377780
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety of anacetrapib in patients with or at high risk for coronary heart disease.
    Cannon CP; Shah S; Dansky HM; Davidson M; Brinton EA; Gotto AM; Stepanavage M; Liu SX; Gibbons P; Ashraf TB; Zafarino J; Mitchel Y; Barter P;
    N Engl J Med; 2010 Dec; 363(25):2406-15. PubMed ID: 21082868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction?
    Schaefer EJ; Asztalos BF
    Curr Opin Cardiol; 2007 Jul; 22(4):373-8. PubMed ID: 17556892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The DEFINE study: a bright future for CETP inhibitors?
    Katsiki N; Athyros VG; Mikhailidis DP
    Expert Opin Investig Drugs; 2011 Mar; 20(3):311-4. PubMed ID: 21235422
    [No Abstract]   [Full Text] [Related]  

  • 11. Trial watch: hope renewed for strategy to raise HDL cholesterol.
    Nat Rev Drug Discov; 2011 Jan; 10(1):10. PubMed ID: 21193857
    [No Abstract]   [Full Text] [Related]  

  • 12. Anacetrapib: hope for CETP inhibitors?
    Gurfinkel R; Joy TR
    Cardiovasc Ther; 2011 Oct; 29(5):327-39. PubMed ID: 20406242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [HDL and CETP in atherogenesis].
    Pöss J; Böhm M; Laufs U
    Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDL cholesterol and atherosclerosis.
    Mazzone T
    Lancet; 2007 Jul; 370(9582):107-108. PubMed ID: 17630020
    [No Abstract]   [Full Text] [Related]  

  • 15. Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.
    Reyes-Soffer G; Millar JS; Ngai C; Jumes P; Coromilas E; Asztalos B; Johnson-Levonas AO; Wagner JA; Donovan DS; Karmally W; Ramakrishnan R; Holleran S; Thomas T; Dunbar RL; deGoma EM; Rafeek H; Baer AL; Liu Y; Lassman ME; Gutstein DE; Rader DJ; Ginsberg HN
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):994-1002. PubMed ID: 26966279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anacetrapib: a potential new therapy for dyslipidemia.
    Robinson LB; Frishman WH
    Cardiol Rev; 2014; 22(5):253-61. PubMed ID: 24618931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDL cholesterol: all hope is not lost after the torcetrapib setback--emerging therapeutic strategies on the horizon.
    Verma N; Figueredo VM
    Am J Ther; 2014; 21(3):222-32. PubMed ID: 22967983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CETP Inhibition: does the future look promising?
    Toth PP
    Curr Cardiol Rep; 2011 Dec; 13(6):559-65. PubMed ID: 21909703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
    Neeli H; Rader DJ
    Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?
    Page MM; Hooper AJ; Burnett JR
    Expert Opin Pharmacother; 2016; 17(2):275-81. PubMed ID: 26642232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.